0 Items
Select Page

West Nile Virus

West Nile Virus (WNV) is a cause of neurological disease and death in humans. WNV reached North America in 1999, resulting in a large and dramatic outbreak that continued to spread throughout the USA in the following years. The US WNV outbreak (1999-2010) highlighted the risk posed by importation of vector-borne pathogens outside of their normal range. Since, the virus has spread and is now widely established from Canada to Venezuela.

The Native Antigen Company offers a range of recombinant West Nile virus antigens and highly specific monoclonal antibodies to support research into the infection and assay development.

West Nile Virus Background

West Nile Virus (WNV) is an enveloped, single-stranded RNA virus that belongs to the Flavivirus genus. WNV is a member of the Japanese encephalitis sero-complex, of the family Flaviviridae, which also includes Japanese encephalitis virus, St. Louis encephalitis and Murray Valley encephalitis virus. In nature, West Nile virus is maintained in a cycle between birds and mosquitoes. However, WNV can also be transmitted to incidental hosts such as humans, horses and other mammals by mosquito vectors.

Since the first human WNV infection was identified in 1937, the virus has continued to spread. West Nile virus is now found in many regions of the world including Africa, Europe, West Asia, North and South America. WNV infection is asymptomatic in 80% of cases, but some individuals can develop severe West Nile fever. The symptoms of West Nile fever include fever, headache, nausea and vomiting. The virus has also been associated with neurological complications and fatalities in less than 1% of infected individuals.

Currently, there is no licensed prophylactic vaccine or specific therapeutic treatment for West Nile virus infection in humans. Prevention of WNV infection is through vector control measures and the use of protective clothing to reduce human-to-human transmission.

Reference

  1. Chancey C, et al (2015). The Global Ecology and Epidemiology of West Nile Virus. Biomed Res Int. 376230.

West Nile Virus Antigens

The Native Antigen Company specialises in development and manufacture of native and recombinant viral antigens. Our recombinant antigens are used by pharmaceutical and IVD manufacturers in vaccine research and serology, where proper folding and glycosylation are vital.

We prepare West Nile virus NS1 protein in our proprietary mammalian cell expression system, which generates highly pure NS1 protein in its glycosylated and predominantly hexameric form. Our West Nile virus antigen is ideal for use in immunoassay development and vaccine R&D.

West Nile Virus Antibodies

We have used our recombinant WNV NS1 protein to raise a panel of specific antibodies to WNV NS1 protein, all of which are highly specific and do not cross-react with NS1 proteins from other flaviviruses, including Dengue, Yellow Fever and Japanese Encephalitis viruses

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Eradicating Malaria: The Role of Diagnostics

Malaria has been a major health threat throughout human history and is still a leading cause of death in many tropical and subtropical countries around the globe. Thanks to renewed efforts over the past two decades, malaria prevalence has reduced by half, making total...

The Immune Evasion Strategies of Lassa Fever Virus

In this blog, we outline the molecular pathogenesis of Lassa viral haemorrhagic fever and introduce our extended range of Lassa Fever virus antigens and antibodies.Viral haemorrhagic fevers Viral haemorrhagic fevers (VHF) are a diverse group of viral illnesses that...

Diphtheria toxin: The nuts and bolts

The Native Antigen Company manufactures high-quality Diphtheria toxin in its native format for a range of applications and is offering a 30% discount on this product for the remainder of 2019. In this blog we explain the structure, mechanism-of-action and applications...

Diagnosing HIV in resource-limited settings

In this blog, we discuss the need for improved point-of-care (PoC) diagnostics for HIV and present the virus's cellular mechanism to illustrate our new range of HIV antigens and antibodies. HIV in the developed world On June 5th 1981 in Los Angeles, California, 5...

Our Product Pipeline

If you’ve been following us on social media recently, you might have noticed that we’ve been releasing a lot of new antigens and antibodies. In this blog, we explain how we use the WHO R&D Blueprint to guide our product development and present some highlights from...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

1 + 12 =

Live Customer Feedback

Join our mailing list

* indicates required